IRMD vs. OFIX, NVRO, EMBC, SIBN, OSUR, SKIN, TMCI, SRDX, ANIK, and PLSE
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include Orthofix Medical (OFIX), Nevro (NVRO), Embecta (EMBC), SI-BONE (SIBN), OraSure Technologies (OSUR), Beauty Health (SKIN), Treace Medical Concepts (TMCI), Surmodics (SRDX), Anika Therapeutics (ANIK), and Pulse Biosciences (PLSE). These companies are all part of the "surgical & medical instruments" industry.
Iradimed (NASDAQ:IRMD) and Orthofix Medical (NASDAQ:OFIX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, community ranking, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.
92.3% of Iradimed shares are held by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are held by institutional investors. 42.6% of Iradimed shares are held by company insiders. Comparatively, 4.7% of Orthofix Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Iradimed currently has a consensus price target of $62.50, suggesting a potential upside of 39.82%. Orthofix Medical has a consensus price target of $15.50, suggesting a potential upside of 13.97%. Given Iradimed's stronger consensus rating and higher probable upside, research analysts clearly believe Iradimed is more favorable than Orthofix Medical.
Iradimed has higher earnings, but lower revenue than Orthofix Medical. Orthofix Medical is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed has a net margin of 26.48% compared to Orthofix Medical's net margin of -20.28%. Iradimed's return on equity of 25.01% beat Orthofix Medical's return on equity.
Orthofix Medical received 158 more outperform votes than Iradimed when rated by MarketBeat users. However, 64.69% of users gave Iradimed an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
Iradimed has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
In the previous week, Iradimed had 9 more articles in the media than Orthofix Medical. MarketBeat recorded 10 mentions for Iradimed and 1 mentions for Orthofix Medical. Iradimed's average media sentiment score of 0.62 beat Orthofix Medical's score of -0.27 indicating that Iradimed is being referred to more favorably in the media.
Summary
Iradimed beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
